Table 2. Association between genomic alterations and patients with WSE.
| ALL (N=42) % (n/N) |
WSE (-) (N=23) % (n/N) |
WSE (+) (N=19) % (n/N) |
p-Value | ||
|---|---|---|---|---|---|
| EGFR | Wild Type | 40.5 (17/42) | 64.7 (11/17) | 35.3 (6/17) | |
| Mutant | 59.5 (25/42) | 48 (12/25) | 52.0 (13/25) | 0.353 | |
| EGFR Exon 7 | Wild Type | 54.8 (23/42) | 69.6 (16/23) | 30.4 (7/23) | |
| Mutant | 45.2 (19/42) | 36.8 (7/16) | 63.2 (12/19) | 0.061 | |
| EGFR by exon | Exon 7 | 40 (10/23) | 40 (4/10) | 60 (6/10) | |
| Exon 7/21 | 24 (6/23) | 33.3 (2/6) | 66.7 (4/6) | ||
| Exon 7/19 | 12 (3/23) | 33.3 (1/3) | 66.7 (2/3) | ||
| Exon 19 | 12 (3/23) | 66.7 (2/3) | 33.1 (1/3) | ||
| Exon 21 | 4 (1/23) | 100 (1/1) | 0 (0/1) | ||
| Exon 2 | 4 (1/23) | 100 (1/1) | 0 (0/1) | ||
| Exon 3 | 4 (1/23) | 100 (1/1) | 0 (0/1) | 0.583 | |
| TP53 | Wild Type | 50.0 (21/42) | 47.6 (10/21) | 52.4 (11/21) | |
| Mutant | 50.0 (21/42) | 61.9 (13/21) | 38.1 (8/21) | 0.536 | |
| SMARCB1 | Wild Type | 54.8 (23/42) | 78.3 (18/23) | 21.7 (5/23) | |
| Mutant | 45.2 (19/42) | 26.3 (5/19) | 73.7 (14/19) | 0.002 | |
| ATM | Wild Type | 57.1 (24/42) | 75 (18/24) | 25.0 (6/24) | |
| Mutant | 42.9 (18/42) | 27.8 (5/18) | 72.2 (13/18) | 0.004 | |
| FGFR | Wild Type | 57.1 (24/42) | 54.2 (13/24) | 45.8 (11/24) | |
| Mutant | 42.9 (18/42) | 55.6 (10/18) | 44.4 (8/18) | 1.000 | |
| HNF1A | Wild Type | 61.9 (26/42) | 57.7 (15/26) | 42.3 (11/26) | |
| Mutant | 38.1 (16/42) | 50 (8/16) | 50 (8/16) | 0.753 | |
| RET | Wild Type | 64.3 (27/42) | 66.7 (18/27) | 33.3 (9/27) | |
| Mutant | 35.7 (15/42) | 33.3 (5/15) | 66.7 (10/15) | 0.055 | |
| KDR | Wild Type | 78.6 (33/42) | 66.7 (22/33) | 33.3 (11/33) | |
| Mutant | 21.4 (9/42) | 11.1 (1/9) | 88.9 (8/9) | 0.006 | |
| VHL | Wild Type | 81 (34/42) | 58.8(20/34) | 41.2 (14/34) | |
| Mutant | 19 (8/42) | 37.5 (3/8) | 62.5 (5/8) | 0.433 | |
| ERBB4 | Wild Type | 81 (34/42) | 58.8 (20/34) | 41.2 (14/34) | |
| Mutant | 19 (8/42) | 37.5 (3/8) | 62.5 (5/8) | 0.433 | |
| MET | Wild Type | 88.1 (37/42) | 54.1 (20/37) | 45.9 (17/37) | |
| Mutant | 11.9 (5/42) | 60 (3/5) | 40 (2/5) | 1.000 | |
| STK11 | Wild Type | 88.1 (37/42) | 54.1 (20/37) | 45.9 (17/37) | |
| Mutant | 11.9 (5/42) | 60.0 (3/5) | 40.0 (2/5) | 1.000 | |
| CTTNB1 | Wild Type | 88.1 (37/42) | 54.1 (20/37) | 45.9 (17/37) | |
| Mutant | 11.9 (5/42) | 60 (3/5) | 40(2/5) | 1.000 | |
| APC | Wild Type | 88.1 (37/42) | 51.4 (19/37) | 48.6 (18/37) | |
| Mutant | 11.9 (5/42) | 80 (4/5) | 20 (1/5) | 0.356 | |
| NOTCH1 | Wild Type | 90.5 (38/42) | 57.9 (22/38) | 42.1 (16/38) | |
| Mutant | 9.5 (4/42) | 25.0 (1/4) | 75.0 (3/4) | 0.313 | |
| CSF1R | Wild Type | 90.5 (38/42) | 57.9 (22/38) | 42.1 (16/38) | |
| Mutant | 9.5 (4/42) | 25.0 (1/4) | 75.0 (3/4) | 0.313 |
Abbreviations: EGFR: Epidermal growth factor receptor (ErbB-1 or HER1) TP53: Tumor protein p53 SMARCB1: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1, ATM: Ataxia telangiectasia mutated gene, FGFR: Fibroblast growth factor receptor, HNF1A: Hepatocyte nuclear factor 1-alpha, RET: rearranged during transfection-receptor tyrosine kinase KDR: Kinase Insert Domain Receptor or Vascular Endothelial Growth Factor Receptor 2 VHL: von Hippel-Lindau tumor suppressor, ERBB4: Human Epidermal Growth Factor Receptor 4, MET: mesenchymal-epithelial transition factor receptor tyrosine kinase gene or Hepatocyte Gr owth Factor Receptor, STK11: Serine/threonine kinase 11 or liver kinase B1 (LKB1), CTTNB1: Catenin Beta 1, APC: Adenomatous polyposis coli gene, NOTCH1: Translocation-Associated Notch Protein TAN-1, CSF1R: Colony Stimulating Factor 1 Receptor.